Oric Pharmaceuticals, Inc. (ORIC) - What Are Analysts Thinking About This Stock?

Key Points

• Analysts are broadly bullish: Oric Pharmaceuticals has a “Moderate Buy” consensus from 16 firms, with 14 buys, one hold and one sell. The average 12-month price target is $21.17 versus a recent share price of $13.17.
• Clinical progress is the main catalyst: Oric reported an 84% systemic response rate and 70% intracranial response rate for enozertinib in first-line non-small-cell lung cancer patients with EGFR atypical mutations, and plans to begin the global Redwood-1 Phase 3 trial in the first half of 2027.
• Investors should note both support and risks: Institutional ownership is high at 95.05%, while the CFO sold 14,000 shares under a pre-arranged Rule 10b5-1 plan. The company remains loss-making and recently missed quarterly EPS estimates.

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been assigned an average rating of "Moderate Buy" from the sixteen research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $21.17.

Several research firms have commented on ORIC. Weiss Ratings reissued a "sell (d-)" rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Leerink Partners began coverage on Oric Pharmaceuticals in a report on Monday, October 5th. They issued an "outperform" rating and a $26.00 target price on the stock. BTIG Research initiated coverage on Oric Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a "buy" rating and a $26.00 target price on the stock. Wall Street Zen upgraded Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, July 25th. Finally, JPMorgan Chase & Co. increased their price target on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an "overweight" rating in a research note on Wednesday, October 14th.

Insider Transactions at Oric Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 14,000 shares of the company's stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total transaction of $189,420.00. Following the sale, the chief financial officer directly owned 69,828 shares of the company's stock, valued at $944,772.84. This represents a 16.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 105,000 shares of company stock valued at $1,432,952. Insiders own 5.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ORIC. BlackRock Inc. purchased a new stake in Oric Pharmaceuticals during the second quarter valued at $73,904,000. Siren L.L.C. lifted its position in Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company's stock valued at $37,987,000 after purchasing an additional 1,990,617 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Oric Pharmaceuticals by 19.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company's stock valued at $18,637,000 after purchasing an additional 244,060 shares during the last quarter. Algert Global LLC grew its stake in shares of Oric Pharmaceuticals by 791.3% in the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company's stock worth $13,162,000 after buying an additional 1,078,943 shares in the last quarter. Finally, Braidwell LP grew its stake in shares of Oric Pharmaceuticals by 7.7% in the 2nd quarter. Braidwell LP now owns 1,214,540 shares of the company's stock worth $13,153,000 after buying an additional 86,500 shares in the last quarter. 95.05% of the stock is owned by hedge funds and other institutional investors.

Oric Pharmaceuticals News Summary

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: Promising enozertinib efficacy: At the ESMO Congress 2026, Oric reported an 84% confirmed systemic objective response rate and a 70% confirmed intracranial response rate in first-line non-small-cell lung cancer patients with EGFR atypical mutations. The data included multiple complete responses in the brain, an important potential advantage in a patient population with substantial baseline CNS metastases. Oric enozertinib ESMO data and Phase 3 announcement
• Positive Sentiment: Phase 3 development planned: Oric plans to advance enozertinib into the global Redwood-1 Phase 3 trial in the first half of 2027. Moving into a registrational study could increase the program’s commercial potential and represents a meaningful development milestone for investors. ORIC plans Phase 3 trial after lung cancer data
• Positive Sentiment: Additional pipeline support: Preclinical and translational findings suggest rinzimetostat may help restore sensitivity to androgen-receptor inhibition in prostate cancer and may retain activity against resistance mutations that can undermine EZH2 inhibitors. These findings are earlier-stage but broaden the potential value of Oric’s pipeline. Oric rinzimetostat prostate cancer data
• Neutral Sentiment: Analyst expectations remain favorable: Oric has a consensus “Moderate Buy” rating and an average price target of $21.17, although analyst opinions are not a substitute for clinical or regulatory success.
• Negative Sentiment: CFO insider selling: CFO Dominic Piscitelli sold 14,000 shares worth approximately $189,420 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced his holdings by 16.7%; while planned transactions may be routine, insider selling can weigh on sentiment.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC opened at $13.17 on Friday. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -9.76 and a beta of 0.99. The firm has a fifty day moving average price of $12.93 and a 200 day moving average price of $11.03. Oric Pharmaceuticals has a fifty-two week low of $7.23 and a fifty-two week high of $14.68.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.02). As a group, research analysts predict that Oric Pharmaceuticals will post -1.53 earnings per share for the current year.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc NASDAQ: ORIC is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.

Oric's pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.